SCHEMBL5540932

SCHEMBL5540932

CCCCn1c(=O)c(C(=O)NCCN(C)S(C)(=O)=O)c(O)c2ncc(Cc3ccc(F)cc3)cc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.43
KMT2A Q03164 6/20 0.43
POLB P06746 2/20 0.41
KDM4E B2RXH2 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
USP2 O75604 3/20 0.41
LMNA P02545 3/20 0.41
TSHR P16473 3/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
MAPT P10636 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
EGLN1 Q9GZT9 2/20 0.40
HTT P42858 5/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
PKM P14618 2/20 0.39
ALOX15 P16050 1/20 0.39
ALOX12 P18054 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
UBE2N P61088 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539155 0.94 EGLN1 (0.40) MEN1KMT2APOLBKDM4ESMN1; SMN2
SCHEMBL5538656 0.92 L3MBTL1 (0.47) MEN1KMT2AKDM4ESMN1; SMN2LMNA
SCHEMBL5540775 0.91 EGLN1 (0.40) MEN1KMT2APOLBKDM4ESMN1; SMN2
SCHEMBL5540898 0.89 MEN1 (0.46) MEN1KMT2AKDM4ETSHREGLN1
SCHEMBL5540787 0.89 EGLN1 (0.41) MEN1KMT2AKDM4ELMNAEGLN1
SCHEMBL5545490 0.88 MEN1 (0.47) MEN1KMT2APOLBKDM4ESMN1; SMN2
SCHEMBL5540640 0.87 MEN1 (0.48) MEN1KMT2APOLBKDM4ESMN1; SMN2
SCHEMBL5540933 0.85 CNR2 (0.40) MEN1KMT2APOLBKDM4ESMN1; SMN2
SCHEMBL5545917 0.83 POLB (0.45) MEN1KMT2APOLBKDM4ESMN1; SMN2
SCHEMBL5538489 0.83 POLB (0.45) MEN1KMT2APOLBKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed
EP-1720856-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-15 EP disclosed
WO-2005077050-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 MEN1 4802/4885KMT2A 502/4885POLB 113/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 MEN1 4837/4885KMT2A 819/4885POLB 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.